Form 4: Moderna CFO's Routine Stock Transactions

Moderna's Chief Financial Officer, James M. Mock, reported the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.

Summary

• James M. Mock, Chief Financial Officer of Moderna, Inc. (MRNA), reported transactions involving the company's common stock.
• On January 5, 2026, 1,452 restricted stock units (RSUs) converted into common stock on a one-for-one basis.
• Following the RSU conversion, 780 shares of common stock were disposed of at a price of $30.86 per share to satisfy tax withholding obligations.
• After these transactions, Mr. Mock directly beneficially owns 43,872 shares of common stock.
• The restricted stock unit award had 25% of shares vest on October 5, 2023, with the remaining shares vesting in twelve equal quarterly installments thereafter.
• Mr. Mock now directly beneficially owns 4,359 derivative securities (Restricted Stock Units).

Sentiment

Score: 5

Explanation: The filing reports routine insider transactions related to equity compensation vesting and tax withholding, which are common and generally do not indicate a significant positive or negative sentiment about the company's prospects.

Positives

• The vesting of 1,452 restricted stock units indicates ongoing equity compensation for the Chief Financial Officer, aligning management's interests with shareholders.

Negatives

• The sale of 780 shares of common stock, while for tax withholding purposes, reduces the direct beneficial ownership of the Chief Financial Officer by that amount.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This is a routine insider transaction, common across all industries, where executives receive equity compensation that vests over time, often leading to sales to cover tax liabilities. It does not reflect specific industry trends for biotechnology or pharmaceuticals.

Stakeholder Impact

• Shareholders: Minimal impact as this is a routine, pre-planned transaction for tax purposes, not a discretionary sale indicating a change in management's view of the company.

Next Steps

• The remaining restricted stock units will continue to vest in twelve equal quarterly installments after October 5, 2023.

Key Dates

Keywords

Moderna, MRNA, Insider Transaction, Form 4, Restricted Stock Units, CFO, Equity Compensation, Stock Sale, Tax Withholding